Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 200 of 276

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659	Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475	Technology appraisal guidance
Obinutuzumab for treating lupus nephritis ID 6420	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder TS ID 11884	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
Oral semaglutide for managing overweight and obesity [ID6188]	Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865	Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]	Technology appraisal guidance
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021	Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]	Technology appraisal guidance
Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399	Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808	Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]	Technology appraisal guidance
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]	Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810	Technology appraisal guidance
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861	Technology appraisal guidance
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]	Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]	Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975	Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]	Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587	Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493	Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance
Pridopidine for treating Huntington's disease TSID 12052	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema ID6137	Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642	Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443	Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356	Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905	Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436	Technology appraisal guidance

Results per page

10
25
50
All